New-onset post-transplant diabetes mellitus after haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide
| Autor: | Kathryn A. Culos, Madan Jagasia, Heidi Chen, Adetola A. Kassim, Wichai Chinratanalab, Katie S. Gatwood, Salyka Sengsayadeth, Brendan L. Mangan, Brian G. Engelhardt, Bhagirathbhai Dholaria, Stacey Goodman, Dilan A Patel, Michael Byrne |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Hematological disorders
medicine.medical_specialty endocrine system Cyclophosphamide Hematopoietic cell business.industry Post transplant cyclophosphamide Incidence (epidemiology) medicine.disease Gastroenterology Article New onset surgical procedures operative Post transplant diabetes mellitus Diabetes mellitus Internal medicine hemic and lymphatic diseases Medicine business medicine.drug |
| Zdroj: | EJHaem |
| ISSN: | 2688-6146 |
| Popis: | Haploidentical hematopoietic cell transplant (haplo-HCT) with post-transplant cyclophosphamide (PTCY) is utilized for patients with hematological disorders but without conventional donors. The effects of new-onset post-transplant diabetes mellitus (PTDM) following haplo-HCT are unknown. We examined PTDM incidence and outcomes after haplo-HCT with PTCY. Patients without diabetes receiving haplo-HCT (n=64) were analyzed for PTDM diagnosis (defined as blood glucose≥ 200 mg/dL). By day 100, 14 (22%) patients developed PTDM (median, 18 days). Hyperglycemia (blood glucose ≥ 200 mg/dL) preceded corticosteroids in 11 (79%) individuals. PTDM patients had increased death/relapse (p=0.029). PTDM occurs frequently, precedes corticosteroids, and leads to inferior outcomes following haplo-HCT. PTDM prophylaxis/treatment may improve HCT survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text